GeneDx (NASDAQ:WGS) Announces Earnings Results

GeneDx (NASDAQ:WGS) announced its quarterly earnings results on Tuesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66, Zacks reports. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Stock Performance

WGS stock opened at $76.35 on Tuesday. GeneDx has a twelve month low of $4.34 and a twelve month high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.10 billion, a P/E ratio of -24.55 and a beta of 2.01. The business’s fifty day moving average is $76.48 and its 200-day moving average is $61.21.

Insider Buying and Selling

In other GeneDx news, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total value of $130,041.36. Following the sale, the chief executive officer now directly owns 3,937 shares in the company, valued at approximately $308,975.76. This trade represents a 29.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kevin Feeley sold 1,137 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the completion of the transaction, the chief financial officer now directly owns 24,731 shares of the company’s stock, valued at $1,888,706.47. This trade represents a 4.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 139,603 shares of company stock valued at $12,223,041 over the last three months. Company insiders own 27.30% of the company’s stock.

Analysts Set New Price Targets

WGS has been the subject of several recent research reports. TD Cowen increased their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Craig Hallum increased their target price on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company increased their price objective on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.